Aclaris Therapeutics
NASDAQ: ACRSWayne, US · Founded 2012 · Delaware corporation · 8 known investors
Find your way into Aclaris Therapeutics
448 people in our graph share verified history with the Aclaris Therapeutics team — schools, employers, funds. One of them is your warm intro.
Teresa Chanunlockedknows Hugh Davis · together at Johnson & Johnson (overlapped)
×5knows the team · via Johnson & Johnson
×4knows the team · via Penn State University
knows the team · via Villanova University
knows the team · via University of Regensburg
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
Founders & leadership
Aclaris Therapeutics was founded in 2012 by Neal Walker, Kamil Ali-Jackson, and Stuart D. Shanler.
NW
Neal WalkerCo-founder
KA
Kamil Ali-JacksonCo-founder
SD
Stuart D. ShanlerinCo-founder
JM
Joseph MonahaninExecutive
HD
Hugh DavisinExecutiveHugh Davis holds a Ph.D. and M.S. in Biochemistry from Villanova University and a B.S. in Chemistry from Gannon University. He has held senior leadership roles at Johnson & Johnson (VP and Head of Biologics Clinical Pharmacology), Biosion (Chief Business and Development Officer), Frontage Laboratories (Chief Business Officer), and currently serves as President and COO at Aclaris Therapeutics, with expertise in biologics discovery and development across oncology, immunology, and other therapeutic areas.
JL
James LoeropExecutive
KB
Kevin BalthaserinExecutiveKevin Balthaser is an Executive Officer at Aclaris Therapeutics, a biotech company developing monoclonal antibodies and small-molecule inhibitors for immune-mediated diseases. He has held finance leadership roles at life science companies and has experience with public company operations, capital markets, and M&A transactions.
CP
Christopher PowalaExecutive
RK
JH
Jesse HallChief Medical Officer
FR
Frank RuffoNamed on SEC filing
Board
AS
Investors · 8
Reported raises · per SEC filings
Form D private placements$171.6M disclosed across 6 of 9 rounds · 1900–2026
▶$80MraisedDec 2024 · 19 investors · PharmaceuticalsRule 506(b)
▶$80MraisedDec 2024 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew SchiffDirector
- Joseph MonahanExecutive Officer
- Anand MehraDirector
- Hugh DavisExecutive Officer, Director
- James LoeropExecutive Officer
- Neal WalkerExecutive Officer, Director
- Vincent MilanoDirector
- William HumphriesDirector
- Kevin BalthaserExecutive Officer
- Christopher MolineauxDirector
- Maxine GowenDirector
- Offering amount
- $80M
- Amount sold
- $80M
- Sales commissions
- $4.8M
- Placement agents
- Cantor Fitzgerald & Co., Leerink Partners LLC
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11MraisedApr 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$11MraisedApr 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David GordonExecutive Officer
- William HumphriesDirector
- Kamil Ali-JacksonExecutive Officer
- Bryan ReasonsDirector
- Maxine GowenDirector
- Vincent MilanoDirector
- Andrew PowellDirector
- Christopher MolineauxDirector
- Andrew SchiffDirector
- Frank RuffoExecutive Officer
- Neal WalkerExecutive Officer, Director
- Anand MehraDirector
- Offering amount
- $11.4M
- Amount sold
- $11M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2018 · 41 investors · PharmaceuticalsRule 506(b)
▶$10MraisedAug 2018 · 41 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew SchiffDirector
- Stephen A. TullmanDirector
- Frank RuffoExecutive Officer
- Anand MehraDirector
- Brett FairExecutive Officer
- Bryan ReasonsDirector
- Andrew PowellDirector
- Christopher MolineauxDirector
- William HumphriesDirector
- Kamil Ali-JacksonExecutive Officer
- Neal WalkerExecutive Officer, Director
- Christopher PowalaExecutive Officer
- Stuart ShanlerExecutive Officer
- Offering amount
- $12.5M
- Amount sold
- $10M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedJun 2016 · 9 investors · PharmaceuticalsRule 506(b)
▶$20MraisedJun 2016 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher PowalaExecutive Officer
- Neal WalkerExecutive Officer, Director
- Richard BierlyDirector
- Stuart ShanlerExecutive Officer
- Steven A. TullmanDirector
- Anand MehraDirector
- Albert ChaDirector
- Kamil Ali-JacksonExecutive Officer
- Christopher MolineauxDirector
- Frank RuffoExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.3M
- Placement agents
- Guggenheim Securities, LLC, William Blair & Company L.L.C.
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$40MraisedSep 2015 · 28 investors · PharmaceuticalsRule 506(b)
▶$40MraisedSep 2015 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kamil Ali-JacksonExecutive Officer
- Neal WalkerExecutive Officer, Director
- Frank RuffoExecutive Officer
- Stephen A. TullmanDirector
- Christopher MolineauxDirector
- Ketan PatelDirector
- Stuart D. ShanlerExecutive Officer
- Anand MehraDirector
- Christopher PowalaExecutive Officer
- Albert ChaDirector
- Offering amount
- $40M
- Amount sold
- $40M
- Proceeds to insiders
- $1.8M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$10.6MraisedOct 2014 · 25 investors · PharmaceuticalsRule 506(b)
▶$10.6MraisedOct 2014 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher PowalaExecutive Officer
- Albert ChaDirector
- Stuart ShanlerExecutive Officer
- Neal WalkerExecutive Officer, Director
- Ketan PatelDirector
- Anand MehraDirector
- Stephen TullmanDirector
- Frank RuffoExecutive Officer
- Kamil Ali-JacksonExecutive Officer
- Offering amount
- $21.3M
- Amount sold
- $10.6M
- Minimum investment
- $4.8K
- Proceeds to insiders
- $1.8M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$158.5Mvaluation at IPOOct 2015 · $11.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Alumis57 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Eli Lilly47 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Bioworld46 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Exelixis41 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Aclaris Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Acquisitions · 1
Early investors' stakes continue via these dealsConfluence Life Sciences
Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
In the news
Frequently asked questions
- What does Aclaris Therapeutics do?
- Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
- Who founded Aclaris Therapeutics?
- Aclaris Therapeutics was founded by Neal Walker, Kamil Ali-Jackson, Stuart D. Shanler in 2012.
- Who are Aclaris Therapeutics's investors?
- Aclaris Therapeutics's investors include Aisling Capital, APERTURE Venture Partners, F-Prime Capital, Foresite Capital, RA Capital, Sofinnova Ventures, Sofinnova Venture Partners, Vivo Capital.
- How much funding has Aclaris Therapeutics raised?
- Aclaris Therapeutics has disclosed $171.6M raised across 6 of its 9 known rounds.
- Where is Aclaris Therapeutics headquartered?
- Aclaris Therapeutics is headquartered in Wayne, US.